The role of tumour necrosis factor alpha and soluble tumour necrosis factor alpha receptors in the symptomatology of schizophrenia

References

• Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 4th Edition. Cambridge, UK: Cambridge University Press; 2013.
   Google Scholar
• Van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, von Meijel B, et al. The five-factor model of the Positive and Negative Syndrome Scale II: A ten-fold cross-validation of a revised model. Schizophr Res 2006;85:280–7.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4th Edition Text Revision. Washington: American Psychiatry Press; 2000.
   Google Scholar
• Lewis S, Escalona PR, Keith SJ. Phenomenology of schizophrenia. In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, 9th ed. Philadelphia: Lipincott Williams and Wilkins; 2009, pp. 1433–50.
   Google Scholar
• Kinney DK, Hintz K, Shearer EM, Barch DH, Riffin C, Whitley K, et al. A unifying hypothesis of schizophrenia: Abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Med Hypotheses 2010;74:555–63.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663–71.
   PubMed Web of Science ®Google Scholar
• Smith RS, Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995;45:135–41.
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Müller N, Riedel M, Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001;56:483–6.
   PubMed Web of Science ®Google Scholar
• Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009;63:257–65.
   PubMed Web of Science ®Google Scholar
• Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Baune BT. Tumor necrosis factor alpha and its receptors in behaviour and neurobiology of adult mice, in the absence of an immune challenge. Behav Brain Res 2015;290:51–60.
   PubMed Web of Science ®Google Scholar
• Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience 2015;302:2–22.
   PubMed Web of Science ®Google Scholar
• Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Koerner H, et al. TNF-α and its receptors modulate complex behaviours and neurotrophins in transgenic mice. Psychoneuroendocrinology 2013;38:3102–14.
   PubMed Web of Science ®Google Scholar
• Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2015;25:3219–28.
   Web of Science ®Google Scholar
• McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009;33:355–66.
   PubMed Web of Science ®Google Scholar
• Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther 2010;128:519–48.
   PubMed Web of Science ®Google Scholar
• Baune BT, Camara ML, Eyre H, Jawahar C, Anscomb H, Koerner H. Tumour necrosis factor alpha mediated mechanisms of cognitive dysfunction. Trends Neurosci 2010;3:263–77.
   Google Scholar
• Teixeira AL, de Sousa RT, Zanetti MV, Brunoni AR, Busatto GF, Zarate CA Jr, et al. Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. Hum Psychopharmacology 2015;30:52–6.
   PubMed Web of Science ®Google Scholar
• Li J, Ramenaden ER, Peng J, Koito H, Volpe JJ, Rosenberg PA. Tumor necrosis factor alpha mediates lipopolysaccha- ride-induced microglial toxicity to developing oligodendrocytes when astrocytes are present. J Neurosci 2008;28:5321–30.
   PubMed Web of Science ®Google Scholar
• McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008;5:45.
   PubMed Web of Science ®Google Scholar
• Pan W, Kastin AJ. TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice. Exp Neurol 2002;174:193–200.
   PubMed Web of Science ®Google Scholar
• Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z, et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 2006;26:9703–12.
   PubMed Web of Science ®Google Scholar
• Takei Y, Laskey R. Interpreting crosstalk between TNF-alpha and NGF: potential implications for disease. Trends Mol Med 2008;14:381–8.
   PubMed Web of Science ®Google Scholar
• Golan H, Levav T, Mendelsohn A, Huleihel M. Involve-ment of tumor necrosis factor alpha in hippocampal development and function. Cereb. Cortex 2004;14:97–105.
   PubMed Web of Science ®Google Scholar
• Neijts M, van Dongen J, Kluft C, Boomsma DI, Willemsen G, de Geus EJ. Genetic architecture of the pro-inflammatory state in an extended twin-family design. Twin Res Hum Genet 2013;16:931–40.
   PubMed Web of Science ®Google Scholar
• Coelho FM, Reis HJ, Nicolato R, Romano-Silva MA, Teixeira MM, Bauer ME, et al. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 2008;15:140–4.
   PubMed Web of Science ®Google Scholar
• Barbosa IG, Huguet RB, Mendonça VA, Sousa LP, Neves FS, Bauer ME, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011;261:139–43.
   PubMed Web of Science ®Google Scholar
• Shu HB, Takeuchi M, Goeddel DV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are com-ponents of the tumor necrosis factor receptor 1 signaling com-plex. Proc Natl Acad Sci USA 1996;93:13973–78.
   PubMed Web of Science ®Google Scholar
• Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001;193:427–34.
   PubMed Web of Science ®Google Scholar
• Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002;22:RC216.
   PubMed Web of Science ®Google Scholar
• Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine Growth Factor Rev 2014;25:453–72.
   PubMed Web of Science ®Google Scholar
• Dopp JM, Mackenzie-Graham A, Otero GC, Merrill JE. Differential expression, cytokine modulation, and specific functions of type-1 and type-2 tumor necrosis factor receptors in rat glia. J Neuroimmunol 1997;75:104–12.
   PubMed Web of Science ®Google Scholar
• Mills NT, Wright MJ, Henders AK, Eyles DW, Baune BT, McGrath JJ, et al. Heritability of Transforming Growth factor-β1 and tumor necrosis factor-receptor type 1 expression and vitamin d levels in healthy adolescent twins. Twin Res Hum Genet 2015;18:28–35.
   PubMed Web of Science ®Google Scholar
• Bette M, Kaut O, Schafer MK, Weihe E. Constitutive expression of p55TNFR mRNA and mitogen-specific up-regulation of TNF alpha and p75TNFR mRNA in mouse brain. J Comp Neurol 2003;465:417–30.
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010;49:1215–28.
   PubMed Web of Science ®Google Scholar
• Ebach DR, Riehl TE, Stenson WF. Opposing effects of tumor necrosis factor receptor 1 and 2 in sepsis due to cecal ligation and puncture. Shock 2005;23:311–8.
   PubMed Web of Science ®Google Scholar
• Carpentier I, Coornaert B, Beyaert R. Function and regulation of tumor necrosis factor receptor type 2. Curr Med Chem 2004;11:2205–12.
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Henkler F, Samel D, Reichwein M, Hausser A, Parmryd I, et al. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J Cell Sci 2002;115:2757–70.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Zoecklein L, Papke L, Gamez J, Denic A, Macura S, et al. Tumor necrosis factor alpha is reparative via TNFR2 [corrected] in the hippocampus and via TNFR1 [corrected] in the striatum after virus-induced encephalitis. Brain Pathol 2009;19:12–26.
   PubMed Web of Science ®Google Scholar
• Longhi L, Perego C, Ortolano F, Aresi S, Fumagalli S, Zanier ER, et al. Tumor necrosis factor in traumatic brain injury: effects of genetic deletion of p55 or p75 receptor. J Cereb Blood Flow Metab 2013;33:1182–9.
   PubMed Web of Science ®Google Scholar
• Yang J, You Z, Kim HH, Hwang SK, Khuman J, Guo S, et al. Genetic analysis of the role of tumor necrosis factor receptors in functional outcome after traumatic brain injury in mice. J Neurotrauma 2010;27:1037–46.
   PubMed Web of Science ®Google Scholar
• Baune BT, Wiede F, Braun A, Golledge J, Arolt V, Koerner H. Cognitive dysfunction in mice deficient for TNF- and its receptors. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1056–64.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Scully P, Dinan TG. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res 2008;160:256–62.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Cattaneo A, Hepgul N, Di Forti M, Aitchison KJ, Janiri L, et al. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun 2013;31:90–5.
   PubMed Web of Science ®Google Scholar
• Falcone T, Carlton E, Lee C, Janigro M, Fazio V, Forcen FE, et al. Does systemic inflammation play a role in pediatric psychosis? Clin Schizophr Relat Psychoses 2015;9:65–78B.
   PubMedGoogle Scholar
• Naudin J, Capo C, Giusano B, Mege J, Azorin J. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 1997;26:227–33.
   PubMed Web of Science ®Google Scholar
• Monteleone P, Fabrazzo M, Tortorella A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 1997;71:11–17.
   PubMed Web of Science ®Google Scholar
• Kowalski J, Blada P, Kucia K, Madej A, Herman ZS. Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia. Schizophr Res 2001;50:169–75.
   PubMed Web of Science ®Google Scholar
• Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology 2009;59:123–9.
   PubMed Web of Science ®Google Scholar
• Francesconi LP, Ceresér KM, Mascarenhas R, Stertz L, Gama CS, Belmonte-de-Abreu P. Increased annexin-V and decreased TNF-α serum levels in chronic-medicated patients with schizophrenia. Psychiatry Res 2011;189:305–11.
   PubMed Web of Science ®Google Scholar
• Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 2011;33:268–74.
   PubMed Web of Science ®Google Scholar
• Dunjic-Kostic B, Jasovic-Gasic M, Ivkovic M, Radonjic NV, Pantovic M, Damjanovic A, et al. Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatr Danub 2013;25:55–61.
   PubMed Web of Science ®Google Scholar
• Kubistova A, Horacek J, Novak T. Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls. Psychiatr Danub 2012;Suppl 1:S153–6.
   Google Scholar
• Erbagci AB, Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 2001;10:109–15.
   PubMed Web of Science ®Google Scholar
• Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JC, et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 2012;46:819–24.
   PubMed Web of Science ®Google Scholar
• Lu LX, Guo SQ, Chen W, Li Q, Cheng J, Guo JH. Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia. Di Yi Jun Yi Da Xue Xue Bao 2004;24:1251–4.
   PubMedGoogle Scholar
• Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990;265:1531–6.
   PubMed Web of Science ®Google Scholar
• Seckinger P, Isaaz S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989;264:11966–73.
   PubMed Web of Science ®Google Scholar
• Gatanaga T, Hwang C, Kohr W, Cappuccini F, Lucci JA, Jeffes E, et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990;87:8781–4.
   PubMed Web of Science ®Google Scholar
• Noto C, Gadelha A, Belangero SI, Spindola LM, Rocha NP, de Miranda AS, et al. Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. J Psychiatr Res 2013;47:467–71.
   PubMed Web of Science ®Google Scholar
• Brietzke E, Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1355–61.
   PubMed Web of Science ®Google Scholar
• Maddahi A, Kruse LS, Chen QW, Edvinsson L. he role of tumor necrosis factor-α and TNF-α receptors in cerebral arteries following cerebral ischemia in rat. J Neuroinflammation 2011;8:107.
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann Rev Med 1994;45:491–503.
   PubMed Web of Science ®Google Scholar
• Hope S, Melle I, Aukrust P, Seten NE, Birkenaes AB, Lorentzen S, et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosisfactor receptor I and von Willebrand factor. Bipolar Disord 2009;11:726–34.
   PubMed Web of Science ®Google Scholar
• Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999;33:407–18.
   PubMed Web of Science ®Google Scholar
• Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res 2013;145:36–42.
   PubMed Web of Science ®Google Scholar
• Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 2004;254:14–22.
   PubMed Web of Science ®Google Scholar
• Maschietto M, Silva AR, Puga RD, Lima L, Pereira CB, Nakano EY, et al. Gene expression of peripheral blood lymphocytes may discriminate patients with schizophrenia from controls. Psychiatry Res 2012;200:1018–21.
   PubMed Web of Science ®Google Scholar
• Lv MH, Tan YL, Yan SX, Tian L, Chen da C, Tan SP, et al. Decreased serum TNF-alpha levels in chronic schizophrenia patients on long-term antipsychotics: correlation with psychopathology and cognition. Psychopharmacology (Berl). 2015;232:165–72.
   PubMed Web of Science ®Google Scholar
• Dean B, Gibbons AS, Tawadros N, Brooks L, Everall IP, Scarr E. Different changes in cortical tumor necrosis factor-α-related pathways in schizophrenia and mood disorders. Mol Psychiatry 2013;18:767–73.
   PubMed Web of Science ®Google Scholar
• Czerski PM, Rybakowski F, Kapelski P, Rybakowski JK, Dmitrzak- Weglarz M, Leszczyńska-Rodziewicz A, et al. Association of tumor necrosis factor-308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology 2008;57:88–94.
   PubMed Web of Science ®Google Scholar
• Naz N, Riaz M, Saleem M. Potential role of Neuregulin 1 and TNF-alpha (-308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan. Mol Biol Rep 2011;38:4709–14.
   PubMed Web of Science ®Google Scholar
• Morar B, Schwab SG, Albus M, Maier W, Lerer B, Wildenauer DB. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2007;144B:318–24.
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Bocchio-Chiavetto L, Valsecchi P, Scassellati C, Pasqualetti P, Bonvicini C, et al. G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: meta-analysis plus association study. Brain Behav Immun 2007;21:450–7.
   PubMed Web of Science ®Google Scholar
• Saviouk V, Chow EWC, Bassett AS, Brzustowicz LM. Tumor necrosis factor promoter haplotype associated with schizophrenia reveals a linked locus on 1q44. Mol Psychiatry 2005;10:375–83.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Muratake T, Kaneko N, Fukui N, Nara Y, Someya T. No association between the tumor necrosis factor-alpha gene promoter polymorphisms and schizophrenia in a Japanese population. Psychiatry Res 2007;153:1–6.
   PubMed Web of Science ®Google Scholar
• Pae CU, Chae JH, Bahk WM, Han H, Jun TY, Kim KS, et al. Tumor necrosis factor-alpha gene polymorphism at position -308 and schizophrenia in the Korean population. Psychiatry Clin Neurosci 2003;57:399–403.
   PubMed Web of Science ®Google Scholar
• Duan S, Xu Y, Chen W, Liu Z, Guo T, Gao J, et al. No association between the promoter variants of tumor necrosis factor alpha (TNF-alpha) and schizophrenia in Chinese Han population. Neurosci Lett 2004;366:139–43.
   PubMed Web of Science ®Google Scholar
• Debnath M, Mitra B, Bera NK, Chaudhuri TK, Zhang YP. Lack of association of IL-6 (-174 G>C) and TNF-α (-238 G>A) variants with paranoid schizophrenia in Indian Bengalee population. Cytokine 2013;61:455–8.
   PubMed Web of Science ®Google Scholar
• Jia P, Wang L, Meltzer HY, Zhao Z. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res 2010;122:38–42.
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Miriam G, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, D.C.: American Psychiatric Press Inc.; 1996.
   Google Scholar
• American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4 ed. Washington: American Psychiatry Press; 1995.
   Google Scholar
• Çorapçıoğlu A, Aydemir Ö, Yıldız M, Esen A, Köroğlu E. DSM-IV Eksen I Bozuklukları için Yapılandırılmış Klinik Görüşme, Klinik Versiyon (SCID-I). (Engl. trans: Structured clinical interview for DSM-IV axis I disorders, clinician version). Hekimler Yayın Birliği, Ankara; 1999.
   Google Scholar
• Kay SR, Fiszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 1987;13:261–76.
   PubMed Web of Science ®Google Scholar
• Kostakoğlu AE, Batur S, Tiryaki A. Pozitif ve Negatif Sendrom Ölçeğinin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenirliği. (Engl. trans.: The reliability and validity of the Turkish adaptation of the Positive and Negative Syndrome Scale (PANSS)). Türk Psikoloji Dergisi 1999;14:23–32.
   Web of Science ®Google Scholar
• Pandey GN, Ren X, Rizavi HS, Zhang H. Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients. Schizophr Res 2015;164:193–8.
   PubMed Web of Science ®Google Scholar